sacituzumab govitecan,rovalpituzumab tesirine,dcvax-l
northwest biotherapeutics,gilead sciences,bms,abbvie
['gbm', 'rova', 'trodelvy', 'nwbo']
 gilead paid 21 billion for immunomedics before trodelvy, which targets one antigen, had full fda approval. no coverage for dcvax except erroneous claims of trial failure despite fact that it helped gbm patients live longer! that heterogeneous cancer has more antigens! #asco22 
Sharing knowledge about #DCVax.  Long $NWBO.

Not investment advice.

Do your own research. 

https://t.co/Vy854YELlC